Literature DB >> 8283054

Fc gamma R-mediated endocytosis and expression of cell surface Fc gamma RIIb1 and Fc gamma RIIb2 by mouse bone marrow culture-derived progenitor mast cells.

R B Lobell1, K F Austen, H R Katz.   

Abstract

Mouse IL-3-dependent, bone marrow culture-derived mast cells (BMMC) bind IgG immune complexes through Fc receptors for IgG (Fc gamma R) but express minimal Fc gamma RIII on their surfaces. BMMC do not degranulate appreciably when their Fc gamma R are perturbed with the rat anti-mouse Fc gamma RII/III mAb 2.4G2 and F(ab')2 mouse anti-rat IgG (MAR). In contrast, after their Fc gamma R were cross-linked with mAb 2.4G2 and Na125I-labeled MAR at 37 degrees C, BMMC rapidly internalized the complex. To identify the Fc gamma R species expressed on the surface of BMMC and therefore implicated in the endocytic response, two rabbit antipeptide antisera were raised, one against a sequence common to the cytoplasmic regions of Fc gamma RIIb1 and Fc gamma RIIb2 and the other to a unique cytoplasmic region of Fc gamma RIIb1. When Fc gamma R were immunoprecipitated with mAb 2.4G2 from detergent extracts of BMMC, digested with N-glycosidase F, subjected to SDS-PAGE, and immunoblotted with the Fc gamma RIIb1- and Fc gamma RIIb1/b2-specific antibodies, BMMC were found to express Fc gamma RIIb1 and Fc gamma RIIb2. Selective immunoprecipitation of plasma membrane-localized Fc gamma RIIb1 and Fc gamma RIIb2 from [3H]leucine-labeled BMMC showed that their ratio at the cell surface was similar to their initial biosynthetic ratio. Thus, in contrast to mature serosal mast cells that degranulate on binding of IgG complexes, immature mast cells, of which BMMC are a prototype, may have a role in the clearance of complexes without concomitant release of proinflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8283054

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Anaphylaxis as a clinical manifestation of clonal mast cell disorders.

Authors:  A Matito; I Alvarez-Twose; J M Morgado; L Sánchez-Muñoz; A Orfao; L Escribano
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

Review 2.  Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis?

Authors:  A Matito; M Carter
Journal:  Curr Allergy Asthma Rep       Date:  2015-05       Impact factor: 4.806

3.  Blocking the inhibitory receptor programmed cell death 1 prevents allergic immune response and anaphylaxis in mice.

Authors:  Jyoti K Lama; Koji Iijima; Takao Kobayashi; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2022-01-29       Impact factor: 14.290

Review 4.  Mastocytosis: Fertility and Pregnancy Management in a Rare Disease.

Authors:  Jacqueline Ferrari; Pietro Benvenuti; Elisa Bono; Nicolas Fiorelli; Chiara Elena
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

5.  Regulation of anaphylactic responses by phosphatidylinositol phosphate kinase type I {alpha}.

Authors:  Junko Sasaki; Takehiko Sasaki; Masakazu Yamazaki; Kunie Matsuoka; Choji Taya; Hiroshi Shitara; Shunsuke Takasuga; Miki Nishio; Katsunori Mizuno; Teiji Wada; Hideyuki Miyazaki; Hiroshi Watanabe; Ryota Iizuka; Shuichi Kubo; Shigeo Murata; Tomoki Chiba; Tomohiko Maehama; Koichi Hamada; Hiroyuki Kishimoto; Michael A Frohman; Keiji Tanaka; Josef M Penninger; Hiromichi Yonekawa; Akira Suzuki; Yasunori Kanaho
Journal:  J Exp Med       Date:  2005-03-14       Impact factor: 14.307

Review 6.  Insights in Anaphylaxis and Clonal Mast Cell Disorders.

Authors:  David González-de-Olano; Iván Álvarez-Twose
Journal:  Front Immunol       Date:  2017-07-10       Impact factor: 7.561

7.  Identification of Shared Genes and Pathways in Periodontitis and Type 2 Diabetes by Bioinformatics Analysis.

Authors:  Junho Kang; Eun Jung Kwon; Mihyang Ha; Hansong Lee; Yeuni Yu; Ji Wan Kang; Yeongjoo Kim; Eun Young Lee; Ji-Young Joo; Hye Jin Heo; Eun Kyoung Kim; Tae Woo Kim; Yun Hak Kim; Hae Ryoun Park
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-25       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.